EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients

Kathrin Niedermayer, Henning Schäffler, Georgios Vlachos, Sara Greco, Kerstin Pfister, Barbara Volz, Leonie Ott iD, Hans Neubauer, Bernhard Polzer iD, André Koch, Sabine Riethdorf, Tanja Fehm und 6 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Kathrin Niedermayer und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Ulm University, Ulm, Germany. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Breast Neoplasms, Drug Resistance, Neoplasm, Homologous Recombination. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Research Training Group, project B03, Deutsche Krebshilfe, Universität Ulm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor cells (CTCs) can serve as a liquid biopsy to gain insight into treatment responses and metastatic recurrence. Due to their rarity, the analysis of CTCs is challenging and commonly based on immunomagnetic technologies using antibodies against EpCAM. This study used mass cytometry (CyTOF®) for the identification and characterization of CTCs from longitudinally monitored metastatic breast cancer (mBC) patients. Functional analysis focused on DNA damage responses, particularly the DNA repair pathway of homologous recombination (HR) validated in BC cells from the pleura. Fifty‐two blood samples from 13 mBC patients were collected for the enumeration of CTCs using CellSearch® technology, isolation of CTCs together with peripheral blood mononuclear cells (PBMCs) and of plasma. Cell‐free DNA (cfDNA) from plasma was analyzed by shallow genome sequencing to determine tumor fraction (TF) and HR deficiency (HRD). CTC/PBMC mixtures were phenotyped by CyTOF® using a panel of 13 antibodies including anti‐γH2AX, 53BP1, and RAD51. CyTOF® identified CTCs correlating with CellSearch®‐ and cfDNA‐based quantifications, detected DNA damage in CTCs, and the dynamics of their HR status during genotoxic therapies. Our study shows that CyTOF®‐based phenotyping of CTCs from mBC patients shows promise as a method to monitor tumor progression and HR proficiency in real time for the identification of chemoresistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingBreast NeoplasmsDrug Resistance, NeoplasmHomologous RecombinationHumansFemaleMiddle AgedBiomarkers, TumorAgedAdultNeoplasm MetastasisFlow Cytometry

Stichwörter der Autor:innen

CTCHRDmass cytometrymetastatic breast cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Ulm University, Ulm, Germany.
  • Institute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
  • Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Medical University of Graz, Graz, Austria.
  • Research Institute for Women's Health, University of Tübingen, Tübingen, Germany.
  • Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Obstetrics and Gynecology, University Hospital Düsseldorf, Düsseldorf, Germany.

ORCID-Profile: Leonie Ott, Bernhard Polzer, Ellen Heitzer, Lisa Wiesmüller

Förderung

  • Deutsche Forschungsgemeinschaft, Research Training Group, project B03
  • Deutsche Krebshilfe
  • Universität Ulm
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Niedermayer, K., Schäffler, H., Vlachos, G., Greco, S., Pfister, K., Volz, B., Ott, L., Neubauer, H., Polzer, B., Koch, A., Riethdorf, S., Fehm, T., Janni, W., Friedl, T. W. P., Rack, B., Heitzer, E., Schochter, F., & Wiesmüller, L. (2025). Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients. International Journal of Cancer. https://doi.org/10.1002/ijc.35498

Vancouver

Niedermayer K, Schäffler H, Vlachos G, Greco S, Pfister K, Volz B, et al. Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients. International Journal of Cancer. 2025. doi:10.1002/ijc.35498

BibTeX
@article{Niedermayer2025,
  author = {Niedermayer, Kathrin and Schäffler, Henning and Vlachos, Georgios and Greco, Sara and Pfister, Kerstin and Volz, Barbara and Ott, Leonie and Neubauer, Hans and Polzer, Bernhard and Koch, André and Riethdorf, Sabine and Fehm, Tanja and Janni, Wolfgang and Friedl, Thomas W P and Rack, Brigitte and Heitzer, Ellen and Schochter, Fabienne and Wiesmüller, Lisa},
  title = {Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35498}
}
Kostenlos starten →